These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25274378)

  • 1. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
    Li H; Fei X; Shen Y; Wu Z
    Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
    Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
    J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
    Parikh H; Wang Z; Pettigrew KA; Jia J; Daugherty S; Yeager M; Jacobs KB; Hutchinson A; Burdett L; Cullen M; Qi L; Boland J; Collins I; Albert TJ; Vatten LJ; Hveem K; Njølstad I; Cancel-Tassin G; Cussenot O; Valeri A; Virtamo J; Thun MJ; Feigelson HS; Diver WR; Chatterjee N; Thomas G; Albanes D; Chanock SJ; Hunter DJ; Hoover R; Hayes RB; Berndt SI; Sampson J; Amundadottir L
    Hum Genet; 2011 Jun; 129(6):675-85. PubMed ID: 21318478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
    Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
    Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
    Bensen JT; Xu Z; Smith GJ; Mohler JL; Fontham ET; Taylor JA
    Prostate; 2013 Jan; 73(1):11-22. PubMed ID: 22549899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men.
    Nobata S; Hishida A; Naito M; Asai Y; Mori A; Kuwabara M; Katase S; Okada R; Morita E; Kawai S; Hamajima N; Wakai K
    Urol Int; 2012; 89(1):39-44. PubMed ID: 22433834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.
    Helfand BT; Roehl KA; Cooper PR; McGuire BB; Fitzgerald LM; Cancel-Tassin G; Cornu JN; Bauer S; Van Blarigan EL; Chen X; Duggan D; Ostrander EA; Gwo-Shu M; Zhang ZF; Chang SC; Jeong S; Fontham ET; Smith G; Mohler JL; Berndt SI; McDonnell SK; Kittles R; Rybicki BA; Freedman M; Kantoff PW; Pomerantz M; Breyer JP; Smith JR; Rebbeck TR; Mercola D; Isaacs WB; Wiklund F; Cussenot O; Thibodeau SN; Schaid DJ; Cannon-Albright L; Cooney KA; Chanock SJ; Stanford JL; Chan JM; Witte J; Xu J; Bensen JT; Taylor JA; Catalona WJ
    Hum Genet; 2015 Apr; 134(4):439-50. PubMed ID: 25715684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.
    Shu X; Ye Y; Gu J; He Y; Davis JW; Thompson TC; Logothetis CJ; Kim J; Wu X
    Carcinogenesis; 2016 Oct; 37(10):965-971. PubMed ID: 27515962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between three genetic variants in kallikrein 3 and prostate cancer risk.
    Ding WH; Ren KW; Yue C; Zou JG; Zuo L; Zhang LF; Bai Y; Okada A; Yasui T; Mi YY
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.
    Hu J; Qiu Z; Zhang L; Cui F
    Diagn Pathol; 2014 Apr; 9():84. PubMed ID: 24755043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
    Xu J; Isaacs SD; Sun J; Li G; Wiley KE; Zhu Y; Hsu FC; Wiklund F; Turner AR; Adams TS; Liu W; Trock BJ; Partin AW; Chang B; Walsh PC; Grönberg H; Isaacs W; Zheng S
    Clin Cancer Res; 2008 Sep; 14(18):5819-24. PubMed ID: 18794092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.
    Jinga V; Csiki IE; Manolescu A; Iordache P; Mates IN; Radavoi D; Rascu S; Badescu D; Badea P; Mates D
    J Cell Mol Med; 2016 Apr; 20(4):594-600. PubMed ID: 26773531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility loci associated with prostate cancer progression and mortality.
    Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
    Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
    Knipe DW; Evans DM; Kemp JP; Eeles R; Easton DF; Kote-Jarai Z; Al Olama AA; Benlloch S; Donovan JL; Hamdy FC; Neal DE; Smith GD; Lathrop M; Martin RM
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1356-1365. PubMed ID: 24753544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
    Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
    Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Choi WS; Kim D; Kim HJ; Myung SC
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):149-56. PubMed ID: 24492489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
    Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
    Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.